Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
$6.22
-$0.11(-3.01%)
At close: 4:00 PM EST
$6.22
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.88 - $7.80
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$427.61M
Enterprise Value$321.18M
Total Cash (Recent Filing)$163.66M
Total Debt (Recent Filing)$17.44M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Mar 19, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding68,748,220
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-1.44
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-446.71
Enterprise Value/Ebitda-3.46
Forecast
1Y Price Target
$11.40Price Target Upside83.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sizeable Equity And Moderate LeverageA sizeable equity base and relatively low absolute debt provide multi-month runway to progress clinical programs and pursue partnerships without immediate refinancing. This structural cushion reduces near-term solvency risk and supports strategic flexibility while trials advance.
Proprietary Delivery PlatformA platform that improves oligonucleotide delivery to target tissues (e.g., muscle) is a durable competitive asset. If validated, it can increase probability of clinical success, enable multiple program launches, and support licensing or collaboration revenue streams over the medium term.
Strengthened Business And Legal LeadershipAdding an experienced CBO/CLO bolsters deal-making, partnership negotiations and regulatory strategy. Strong commercial and legal leadership can materially reduce execution risk around trial readouts and licensing, improving odds of durable strategic transactions and funding options.
Bears Say
No Revenue And Large Net LossesThe absence of operating revenue and sustained, large net losses mean the company remains entirely pre-commercial and dependent on successful trials to achieve profitability. This structural profile elevates long-term execution risk and makes funding success central to viability.
High Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow at scale forces ongoing external financing or partnerships. Over months, this increases dilution risk, can constrain R&D scope, and creates vulnerability if capital markets tighten or deal timing slips relative to cash runway.
Option Repricing & Retention Dilution RiskRepricing underwater options addresses retention but signals weak shareholder returns and can raise future dilution and compensation expense. Structurally, it may alter incentive alignment and increase share-count risk if similar measures recur to retain key staff through pivotal milestones.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $0.88 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $427.61M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 16 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Nov 12, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.565 by $0.045.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.37.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 68,748,220 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.565. Following the earnings report the stock price went up 10.323%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.40 (83.28% Upside)
$11.40 (83.28% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-62.25%
Trailing 12-Months
Asset Growth
-47.16%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$11.40
▲(83.28% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---